EvoNext Holdings Ltd, previously Evolva Holding Ltd, is a Switzerland-based Company operating as a researcher for biotechnology. The Company develops and commercializes nature-based ingredients. The ingredients, produced by the Company, can be employed in, but not limited to, flavorings fragrancies, health ingredients, health protection and other various sectors. The objectives of the Company are as follows: develop technology platforms - combines biology with technology to produce nature-based ingredients; provide technology services- provides tailored services to clients across industries. The Company is focused on developing and increasing the return and effectiveness of the production of numerous ingredients within their portfolio.

Employees

Sector

Biotechnology & Medical Research

More about the company

12/10	Ascend Sport Technology to List on SIX Swiss Exchange via EvoNext Merger	MT
12/10	Ascend Sport Technology AG signed a binding transaction agreement to acquire EvoNext Holdings SA for approximately CHF 500 million in a reverse merger transaction.	CI

Market Cap	1.64Cr 1.99Cr 1.78Cr 1.48Cr 2.77Cr 188.68Cr 2.82Cr 20Cr 7.84Cr 99Cr 7.46Cr 7.3Cr 313Cr	P/E 2024	6.22x	P/E 2025	-8.95x
Enterprise Value	1.05Cr 1.27Cr 1.14Cr 94.82L 1.77Cr 120.61Cr 1.81Cr 12Cr 5.01Cr 63Cr 4.77Cr 4.67Cr 200.09Cr	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	62.03%	Yield 2024 *	-	Yield 2025	-

12/10	Ascend Sport Technology to List on SIX Swiss Exchange via EvoNext Merger	MT
12/10	Ascend Sport Technology AG signed a binding transaction agreement to acquire EvoNext Holdings SA for approximately CHF 500 million in a reverse merger transaction.	CI
30/09	EvoNext Holdings SA Reports Earnings Results for the Half Year Ended June 30, 2026	CI
30/09	EvoNext Holdings' H1 Net Loss Widens; Financial Income Up	MT
18/08	Evonext Holds Talks to Take Ascend Sport Public	CI
18/08	EvoNext in Advanced Negotiations with Ascend Sport Technology for Reverse Merger	MT
17/08	Switzerland's Ascend Sport Technology Mulls Reverse Merger With EvoNext	MT
17/08	Switzerland's Ascend Sport Technology Mulls Reverse Merger With EvoNext	MT
30/04	EvoNext Holdings SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
21/25/21	EvoNext Holdings SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25/25/25	Evolva Shareholders OK Proposed Renaming to EvoNext	MT
25/25/25	Evolva Holding SA has Changed its Name to EvoNext Holdings SA	CI
23/25/23	Evolva to Not Receive Earn-out Payments from Unit's Buyer	MT

12/10	EvoNext Holdings SA and Ascend Sport Technology AG sign transaction agreement	EQ
30/09	EvoNext Holdings SA publishes half-year report 2026	EQ
17/08	EvoNext Holdings SA confirms advanced discussions on a reverse merger with Ascend Sport Technology AG	EQ
20/05	EvoNext : Minutes of Annual General Meeting 2026	PU
20/05	EvoNext shareholders approve all motions proposed by the Board at the Annual General Meeting 2026	EQ

12/10	Ascend Sport Technology sbarcherà in borsa
12/10	Sporttech-Firma Ascend will durch Fusion mit EvoNext an Schweizer Börse
12/10	Evonext und Ascend Sport einigen sich auf Fusion
12/10	Evonext Holding (ex-Evolva): fusion inversée avec Ascend Sport Technology
30/09	Evonext will Ascend-Transaktion bis Ende 2026 abschliessen

ARPIDA Share Price Swiss Exchange

Stocks

ARPN

Biotechnology & Medical Research

Valuation: ARPIDA

Latest news: ARPIDA

Analysts' recommendations: ARPIDA

Press Releases: ARPIDA

News in other languages: ARPIDA

Managers and Directors: ARPIDA

Other Biotechnology & Medical Research

Financials

Company Profile

Director	Title	Age	Since
Francesco Defila BRD	Director/Board Member	-	27/03/2025
Gianluca Ferrari CHM	Chairman	-	27/03/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-0.62%	-1.87%	+42.87%	+67.17%	6.38TCr
ARGENX SE	+0.35%	+3.20%	+14.40%	+73.89%	5.64TCr
LONZA GROUP AG	+0.53%	+1.96%	+16.24%	+102.20%	5.46TCr
IQVIA HOLDINGS INC.	-2.81%	-4.31%	+23.50%	+48.51%	4.41TCr
BEONE MEDICINES AG	-0.33%	-1.93%	+19.28%	+104.26%	4.21TCr
REVOLUTION MEDICINES, INC.	+0.55%	+2.31%	+225.14%	+840.10%	4.1TCr
GENMAB A/S	+3.27%	+47.96%	+112.84%	+91.02%	3.49TCr
CELLTRION, INC.	+1.22%	-1.44%	+14.57%	+47.05%	3.28TCr
INSMED INCORPORATED	+0.89%	+20.55%	-40.62%	+350.50%	2.47TCr
Average	+0.34%	+7.54%	+47.58%	+191.63%	4.38TCr
Weighted average by Cap.	+0.18%	+5.44%	+47.99%	+173.41%

	2024	2025
Net sales	-	-
Net income	10.44L 12.67L 11.35L 9L 17.68L 12Cr 18.01L 1.24Cr 49.97L 6.33Cr 47.55L 46.54L 20Cr	-7L -8L -7L -6L -11.05L -7.52Cr -11.26L -77.84L -31.25L -3.96Cr -29.73L -29.1L -12Cr
Net Debt	-67.53L -81.98L -73.42L -61.19L -1.14Cr -78Cr -1.17Cr -8.05Cr -3.23Cr -41Cr -3.08Cr -3.01Cr -129.12Cr	-59.06L -71.69L -64.2L -53.51L -1Cr -68Cr -1.02Cr -7.04Cr -2.83Cr -36Cr -2.69Cr -2.63Cr -112.92Cr

End-of-day quote Swiss Exchange
- ^CHF	-